[Sleep disorders in Parkinson's disease: insomnia and sleep fragmentation, daytime hypersomnia, alterations to the circadian rhythm and sleep apnea syndrome].
BACKGROUND
Sleep disorders in Parkinson's disease are present in 60-98% of patients and reduce their quality of life.


OBJECTIVE
To review the pathophysiology, diagnostic approach and management of the different sleep disorders.


METHODS
We describe the pathophysiology associated with neurodegeneration, due to symptoms (motor and nonmotor) and drug therapies. This article reviews insomnia, excessive daytime sleepiness, circadian sleep disorders and sleep apnea.


CONCLUSIONS
Subjective or objective sleepiness assessment should routinely be performed by physicians looking after Parkinson's disease patients. Management is difficult and should be targeted to the specific sleep disorder and its likely cause.
Mondragón-Rezola
E
E
Hospital Donostia, San Sebastián, Guipúzcoa, España. elisabet.mondragonrezola@osakidetza.net
Arratíbel-Echarren
I
I
Ruiz-Martínez
J
J
Martí-Massó
J F
JF
D000978:Antiparkinson Agents / Q000627:therapeutic use; D021081:Chronobiology Disorders / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology* / Q000628:therapy; D006970:Disorders of Excessive Somnolence / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology* / Q000628:therapy; D006801:Humans; D010300:Parkinson Disease / Q000150:complications / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy; D011788:Quality of Life; D012891:Sleep Apnea Syndromes / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology* / Q000628:therapy; D012892:Sleep Deprivation / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology* / Q000628:therapy; D007319:Sleep Initiation and Maintenance Disorders / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology* / Q000628:therapy
D000978:Antiparkinson Agents